- Home
- NODK vs CERS Comparison
NODK vs CERS Comparison
Compare NODK & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- CERS
- Stock Information
- Founded
- NODK 1946
- CERS 1991
- Country
- NODK United States
- CERS United States
- Employees
- NODK N/A
- CERS N/A
- Industry
- NODK Property-Casualty Insurers
- CERS EDP Services
- Sector
- NODK Finance
- CERS Technology
- Exchange
- NODK Nasdaq
- CERS Nasdaq
- Market Cap
- NODK 322.1M
- CERS 324.3M
- IPO Year
- NODK 2017
- CERS 1997
- Fundamental
- Price
- NODK $15.85
- CERS $1.78
- Analyst Decision
- NODK
- CERS Buy
- Analyst Count
- NODK 0
- CERS 3
- Target Price
- NODK N/A
- CERS $3.17
- AVG Volume (30 Days)
- NODK 31.2K
- CERS 2.2M
- Earning Date
- NODK 11-15-2024
- CERS 10-30-2024
- Dividend Yield
- NODK N/A
- CERS N/A
- EPS Growth
- NODK N/A
- CERS N/A
- EPS
- NODK N/A
- CERS N/A
- Revenue
- NODK $380,700,000.00
- CERS $176,229,000.00
- Revenue This Year
- NODK N/A
- CERS $23.85
- Revenue Next Year
- NODK N/A
- CERS $10.89
- P/E Ratio
- NODK N/A
- CERS N/A
- Revenue Growth
- NODK 15.43
- CERS 14.71
- 52 Week Low
- NODK $12.02
- CERS $1.38
- 52 Week High
- NODK $16.55
- CERS $2.59
- Technical
- Relative Strength Index (RSI)
- NODK 56.81
- CERS 55.52
- Support Level
- NODK $15.37
- CERS $1.59
- Resistance Level
- NODK $16.09
- CERS $1.83
- Average True Range (ATR)
- NODK 0.22
- CERS 0.12
- MACD
- NODK 0.01
- CERS 0.02
- Stochastic Oscillator
- NODK 70.93
- CERS 93.55
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.